Canna~Fangled Abstracts

Cannabinoids and their therapeutic applications in mental disorders

By September 23, 2020November 11th, 2020No Comments

doi: 10.31887/DCNS.2020.22.3/pfadda.

Affiliations 

Abstract

Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the endocannabinoid system and its role in multiple physiological processes, both natural and synthetic cannabinoids have attracted considerable interest as putative medications in pathological conditions such as, but not exclusive to, mental disorders. Here, we provide a summary of cannabinoid effects in support of possible therapeutic applications for major depression, bipolar disorder, anxiety, posttraumatic stress disorder, and schizophrenia. Considering this evidence, highlighted benefits and risks of cannabinoid use in the management of these illnesses require further experimental study. .

 

Keywords: anxiety, cannabinoid, cannabis, depression, mental disorders, pharmacotherapy, psychosis

Similar articles

 See all similar articles

References

    1. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 2008;41(2):48–53. – PMC – PubMed
    1. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology. 2009;34(8):1257–1262. – PMC – PubMed
    1. Meyer JD, Crombie KM, Cook DB, Hillard CJ, Koltyn KF. Serum endocannabinoid and mood changes after exercise in major depressive disorder. Med Sci Sports Exerc. 2019;51(9):1909–1917. – PMC – PubMed
    1. Kranaster L, Hoyer C, Aksay SS, et al Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. Eur Arch Psychiatry Clin Neurosci. 2017;267(8):781–786. – PubMed
    1. Hungund BL, Vinod KY, Kassir SA, et al Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry. 2004;9(2):184–190. – PubMed

Leave a Reply